INTRODUCTION: We retrospectively evaluated the efficacy of three-dimensional conformal radiotherapy (3D-CRT) for @entity808 . METHODS: Nine @entity1 with @entity808 were treated with 3D-CRT. All @entity1 had a paravertebral or intraosseous component. @entity5 sizes ranged from 0.8 to 8.7  cm, with a median of 3.5  cm. The prescribed dose was 50  Gy in 25 fractions at the isocenter, except for 1 @entity1 who received 66  Gy in 33 fractions for a large @entity5 . The follow-up period ranged from 20 to 137  months, with a median of 72  months. RESULTS: @entity5 shrinkage within 3  mm occurred in 4 @entity1 and @entity5 expansion within 3  mm occurred in 3. One @entity5 showed neither expansion nor shrinkage at the last follow-up. One @entity1 experienced transient expansion by 8  mm in diameter at 12  months after the completion of radiotherapy (35-43  mm), and then the @entity5 size remained unchanged for 7  years. No severe late @entity137 >=  grade 3 was observed. CONCLUSIONS: Only 1 of 9 @entity5 showed transit expansion over 3  mm after 3D-CRT, and severe late radiation @entity137 was not observed. Use of 3D-CRT should be considered a treatment option for @entity808 .

Three-dimensional conformal fractionated radiotherapy for XXXX with a paravertebral or an intraosseous component.

@entity808 :: ('MESH:D009442', 'Disease') :: ['spinal schwannoma'] @entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'sacral tumor', 'Tumor', 'tumors']
@entity808 :: (MESH:D009442,Disease) :: ['spinal schwannoma']
